What are the main anti-inflammatory compounds in Asteraceae plants?

The primary anti-inflammatory compounds in Asteraceae species are sesquiterpene lactones (STLs)—specifically germacranolides and guaianolides—which alkylate IKKβ to inhibit NF-κB signaling, and chlorogenic acid derivatives such as trans-3,5-O-dicaffeoylquinic acid (3,5-O-diCQA), which modulate ROS and pro-inflammatory cytokine cascades. Flavonoids including apigenin (0.47–2.52 mg/g) and quercetin glycosides (1.63–34.54 mg/g) additionally inhibit COX and LOX enzymes, reducing prostaglandin E₂ and leukotriene synthesis. Together these compound classes create a multi-target anti-inflammatory profile documented in in vitro models, though human clinical confirmation is still lacking.

Is there clinical trial evidence for Asteraceae plant extracts in humans?

Currently, no human randomized controlled trials with defined sample sizes or clinical effect sizes have been published specifically for the antiviral, anti-inflammatory, or antiproliferative properties of Asteraceae spp. as reviewed here; all quantitative efficacy data derives from in vitro cell-based assays. The strongest preclinical findings include DENV-2 antiviral selectivity indices of 18.8–171.0 for crude extracts and EC₅₀ values of 3.1–6.8 µM for isolated STLs. Individual species such as chamomile (Chamaemelum nobile) and arnica (Arnica montana) have species-specific EMA monographs and limited clinical studies, but genus-wide clinical evidence is absent.

Are Asteraceae supplements safe for people with plant allergies?

Individuals with Compositae or Asteraceae family allergy—affecting approximately 5% of atopic populations—face significant cross-reactivity risk across multiple species including chamomile, arnica, yarrow, and tansy, potentially triggering contact dermatitis, allergic rhinitis, or systemic hypersensitivity reactions. Sesquiterpene lactones, particularly parthenolide and related compounds, are the primary allergens responsible for Compositae sensitivity syndrome. Anyone with known allergy to any daisy-family plant (e.g., ragweed, chrysanthemum, marigold) should avoid Asteraceae-derived supplements without prior allergy evaluation.

What is the polyphenol content of goldenrod and tansy extracts?

Goldenrod (Solidago spp.) leaves contain up to 50.99 mg GAE/g DW total polyphenols, with chlorogenic acid derivatives at 0.46–8.41 mg/g, hyperoside at 4.40–7.70 mg/g, and quercetin glycosides reaching 1.63–34.54 mg/g depending on species and extraction conditions. Tansy (Tanacetum spp.) leaves yield even higher total polyphenol concentrations, up to 80.14 mg/g, making it among the richest Asteraceae sources of phenolics. Antioxidant capacity across both species correlates statistically with total polyphenol content (p < 0.05), as demonstrated in comparative phytochemical studies.

What is the recommended dosage for Asteraceae-based supplements?

No universally validated supplemental dose exists for Asteraceae spp. as a category; dosing guidance must be referenced to individual species with EMA or national pharmacopoeia monographs. For chamomile, traditional infusions use 1–2 g dried flowers per cup (2–3 times daily); standardized chamomile extracts in capsule form typically provide 300–600 mg standardized to 0.5–1.0% apigenin. For goldenrod, European phytomedicine uses hydroalcoholic extracts standardized to hyperoside; arnica is restricted to topical use at 0.5–1.0% STLs, as internal doses are toxic. Research-grade extract concentrations of 125–1000 µg/mL used in cell assays do not translate directly to safe human dosing.

Does Asteraceae extract bioavailability improve when taken with food or on an empty stomach?

Asteraceae extracts, particularly those rich in caffeoylquinic acid (CQA) derivatives and sesquiterpene lactones, show improved absorption when consumed with meals containing dietary fats, which enhances lipophilic compound uptake. Taking Asteraceae supplements with food may also reduce potential gastrointestinal irritation from sesquiterpene lactones while supporting more stable blood levels of active constituents. However, individual absorption varies based on extract type (aqueous vs. lipophilic) and digestive function.

Are there differences in anti-inflammatory potency between dried Asteraceae plant material, standardized extracts, and fresh preparations?

Standardized extracts typically deliver consistent levels of sesquiterpene lactones and CQA derivatives, making them more reliable for anti-inflammatory effect compared to dried plant material, which varies by harvest season and storage conditions. Fresh plant preparations may retain heat-sensitive polyphenols but often contain lower concentrations of active lactones than concentrated extracts. For therapeutic intent, standardized extracts are generally preferred in research and clinical applications due to reproducible composition and potency.

Which Asteraceae species show the strongest in vitro evidence for NF-κB inhibition and ROS modulation?

Chamomile (Matricaria chamomilla), chicory (Cichorium intybus), and milk thistle (Silybum marianum) demonstrate robust in vitro suppression of NF-κB signaling and oxidative stress markers through their sesquiterpene lactones and chlorogenic acid content. Arnica montana and echinacea species also exhibit significant ROS-scavenging activity in cellular models, though human clinical data remains limited for many species. The strength of these effects correlates with the concentration and bioavailability of specific phenolic and sesquiterpene constituents in each species.

Asteraceae

Asteraceae species deliver anti-inflammatory and antioxidant effects primarily through sesquiterpene lactones (STLs), chlorogenic acid derivatives, quercetin glycosides, and apigenin-based flavonoids that modulate NF-κB signaling, COX/LOX pathways, and free radical scavenging. In vitro studies demonstrate notable antiviral activity against dengue virus serotype 2 (DENV-2), with STL isolates achieving EC₅₀ values of 3.1–6.8 µM and selectivity indices exceeding 73.4, though human clinical trial data remain absent from the current literature.

Category: South American Evidence: 1/10 Tier: Preliminary

Origin & History

The Asteraceae family—the largest family of flowering plants with over 32,000 species—is distributed globally but is particularly diverse in South America, the Mediterranean basin, and temperate regions of Europe and Asia. Key medicinal species include Achillea millefolium (yarrow) native to Europe and western Asia, Arnica montana from alpine European meadows, Solidago spp. (goldenrod) widespread across North America and Europe, Tanacetum spp. (tansy) native to temperate Europe and Asia, and Chamaemelum nobile (Roman chamomile) from western Europe and North Africa. Cultivation is strongly recommended over wild harvest, particularly for endangered species such as Helichrysum arenarium, to ensure chemical consistency and ecological sustainability.

Historical & Cultural Context

Asteraceae species have been integral to traditional medicine systems across Europe, Asia, and the Americas for millennia; yarrow (Achillea millefolium) is referenced in ancient Greek texts attributed to the mythological hero Achilles, who reportedly used it to stanch battlefield wounds, reflecting early recognition of its hemostatic and anti-inflammatory properties. Arnica montana has been embedded in Central European folk medicine since at least the 16th century, used in poultices and tinctures for blunt trauma, muscle pain, and bruising, and remains one of the most widely used homeopathic and phytotherapeutic agents in Germany today. Goldenrod (Solidago spp.) was extensively employed by Native American tribes for wound healing, kidney support, and respiratory ailments, while tansy (Tanacetum vulgare) served in medieval European herbalism as an anthelmintic and emmenagogue, though its thujone content raised later toxicity concerns. Burdock (Arctium lappa) holds significant traditional roles in Chinese medicine (niúbàng) and Japanese cuisine and medicine (gobō), valued for its root's detoxifying, hepatoprotective, and antidiabetic applications across Asian traditional healing systems.

Health Benefits

- **Anti-inflammatory Activity**: Sesquiterpene lactones (germacranolides and guaianolides) and caffeoylquinic acid (CQA) derivatives suppress inflammatory cascades, with inferred inhibition of NF-κB and modulation of reactive oxygen species (ROS), reducing pro-inflammatory cytokine signaling observed in cellular models.
- **Antioxidant Capacity**: Phenolic compounds including chlorogenic acid derivatives (0.46–8.41 mg/g in tansy and goldenrod), hyperoside (4.40–7.70 mg/g), and quercetin glycosides (1.63–34.54 mg/g) scavenge free radicals with antioxidant capacity statistically correlated with total polyphenol content (p < 0.05).
- **Antiviral Properties**: STLs isolated from select Asteraceae species inhibit DENV-2 replication with EC₅₀ values of 3.1–6.8 µM and selectivity indices >73.4, while crude extracts achieve EC₅₀ values of 0.11–3.85 µg/mL with selectivity indices of 18.8–171.0, suggesting direct viral enzyme inhibition.
- **Cytotoxic and Antiproliferative Effects**: High-concentration polyphenol extracts (500–1000 µg/mL from goldenrod and tansy) reduce cancer cell viability to 47–82% of controls in MTS assays, disrupting cell adherence and proliferative signaling through polyphenolic modulation of intracellular pathways.
- **Hepatoprotective and Antidiabetic Support**: Arctium spp. (burdock) within Asteraceae exhibit traditional and preclinical evidence for hepatoprotective and antidiabetic effects, attributed to phenolic compounds and polysaccharides modulating oxidative stress and glucose metabolism.
- **COX/LOX Pathway Modulation**: Flavonoids in Chamaemelum nobile and apigenin derivatives (0.47–2.52 mg/g) are associated with inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, contributing to reduction of prostaglandin and leukotriene synthesis based on in vitro correlations.
- **Antioxidant-Polyphenol Synergy**: Total polyphenol concentrations reaching 80.14 mg/g in tansy leaves and 50.99 mg GAE/g DW in goldenrod leaves provide a broad-spectrum antioxidant matrix, with isorhamnetin glycosides adding complementary radical-scavenging activity distinct from primary CQA mechanisms.

How It Works

Sesquiterpene lactones (STLs), particularly germacranolides and guaianolides, exert anti-inflammatory and antiviral effects through electrophilic alkylation of cysteine residues on target proteins, including IKKβ within the NF-κB pathway, thereby suppressing transcription of pro-inflammatory mediators; STL compounds 6–8 additionally inhibit DENV-2 replication via direct viral enzyme interference with EC₅₀ values of 3.1–6.8 µM. Chlorogenic acid derivatives—particularly trans-3,5-O-dicaffeoylquinic acid (3,5-O-diCQA) and caffeoyl-deoxy-octulopyranosonic acids—act as potent free radical scavengers and modulate cytotoxic signaling in cancer cell lines, likely through ROS reduction and disruption of proliferative kinase cascades. Flavonoids including apigenin, hyperoside, and quercetin glycosides competitively inhibit COX and LOX enzymes, reducing prostaglandin E₂ and leukotriene B₄ synthesis, while isorhamnetin glycosides contribute additional antioxidant activity through electron donation and metal chelation. At concentrations of 500–1000 µg/mL, polyphenol-rich extracts induce cytotoxicity in adherent cell lines by disrupting cytoskeletal integrity and cell signaling, whereas lower doses (125–250 µg/mL) may paradoxically promote cell viability, indicating dose-dependent and biphasic polyphenolic modulation of cellular homeostasis.

Scientific Research

Available evidence for Asteraceae spp. is predominantly preclinical, comprising in vitro bioassays and phytochemical characterization studies with no human randomized controlled trials identified in the current literature for the specific antiviral, anti-inflammatory, or cytotoxic applications described. Antiviral activity against DENV-2 has been documented in cell-based antiviral assays, with selectivity indices of 18.8–171.0 for crude extracts and >73.4 for isolated STLs, representing reproducible in vitro findings but requiring in vivo validation before clinical translation. Cytotoxicity and antiproliferative effects in goldenrod and tansy extracts have been characterized through MTS cell viability assays demonstrating 47–82% viability retention at 125–1000 µg/mL, with statistical correlation between total polyphenol content and antioxidant capacity (p < 0.05) across multiple species. The body of evidence reflects high phytochemical characterization quality but critically lacks pharmacokinetic, bioavailability, dose-escalation, and clinical efficacy data, confining current confidence to mechanism-hypothesis generation rather than therapeutic recommendation.

Clinical Summary

No human clinical trials with defined sample sizes, randomization protocols, or quantified clinical effect sizes have been identified for Asteraceae spp. in the context of their sesquiterpene lactone, phenolic, or flavonoid constituents applied to anti-inflammatory, antiviral, or anticancer endpoints. The entirety of quantitative outcome data derives from in vitro experiments: DENV-2 antiviral EC₅₀ values of 0.11–3.85 µg/mL (crude extracts) and 3.1–6.8 µM (isolated STLs), and MTS-based cytotoxicity assays showing concentration-dependent reductions in cancer cell viability. Confidence in clinical applicability is low; while the in vitro selectivity indices (up to 171.0 for antiviral activity) are promising, translation to effective and safe human dosing requires pharmacokinetic profiling, bioavailability studies, and phase I–II clinical investigation. Until such data are generated, Asteraceae-derived preparations should be regarded as candidates for further investigation rather than evidence-based therapeutic agents.

Nutritional Profile

Asteraceae species are not consumed as bulk macronutrient sources; their nutritional relevance lies in concentrated phytochemicals rather than caloric constituents. Total polyphenol content varies dramatically by species and plant part: tansy leaves yield up to 80.14 mg/g total polyphenols and goldenrod leaves up to 50.99 mg GAE/g DW, with quercetin glycosides (1.63–34.54 mg/g), hyperoside (4.40–7.70 mg/g), chlorogenic acid derivatives (0.46–8.41 mg/g), and apigenin derivatives (0.47–2.52 mg/g) as primary quantified constituents. Sesquiterpene lactones (STLs) including germacranolides and guaianolides are present in species such as Arnica montana and Achillea millefolium, contributing anti-inflammatory and cytotoxic bioactivity at sub-milligram per gram concentrations. Phytosterols and polysaccharides are additional biologically active components; phenolic bioavailability is moderately enhanced in glycoside form (e.g., hyperoside, quercetin-3-glucoside) compared to aglycone forms, as glycosides facilitate intestinal transport via sodium-dependent glucose transporters prior to hydrolysis.

Preparation & Dosage

- **Traditional Infusion (Tea)**: Dried flowers or leaves of yarrow, chamomile, or goldenrod prepared as 1–2 g herb per 200 mL boiling water, steeped 5–10 minutes; consumed 2–3 times daily in traditional European herbalism.
- **Hydroalcoholic Extract (Tincture)**: 1:5 tincture in 25–45% ethanol; typical traditional dose 2–4 mL three times daily, though no clinical trial-validated dose exists for the species reviewed.
- **Standardized Dry Extract (Capsule/Tablet)**: Extracts standardized to specific markers (e.g., 0.5–1.0% apigenin for chamomile; 0.5% hyperoside for goldenrod) used in European phytomedicine; typical encapsulated dose 300–600 mg per serving.
- **Research-Grade Methanol/Dichloromethane Extract**: Used in bioassays at 125–1000 µg/mL; these concentrations are not directly translatable to human supplemental doses and should not guide self-dosing.
- **Arnica Topical Preparation**: Arnica montana preparations standardized to 0.5–1.0% sesquiterpene lactones applied topically for bruising and inflammation; internal use is contraindicated due to toxicity at systemic doses.
- **Standardization Note**: No universally accepted human supplemental dosing standard exists across Asteraceae spp.; product labeling and European Medicines Agency (EMA) monographs for individual species (e.g., chamomile, yarrow) provide the most reliable species-specific guidance.

Synergy & Pairings

Quercetin glycosides from Asteraceae species demonstrate enhanced anti-inflammatory synergy when combined with bromelain (from pineapple stem), as bromelain improves quercetin intestinal absorption by up to 40% while independently inhibiting pro-inflammatory cytokine synthesis via protease-mediated pathways. The combination of CQA-rich Asteraceae extracts with vitamin C (ascorbic acid) may regenerate oxidized phenolic radicals back to their active antioxidant forms, extending the free radical scavenging cycle and amplifying total antioxidant capacity beyond additive predictions. STL-containing Asteraceae preparations are theoretically complementary to omega-3 fatty acids (EPA/DHA), as EPA/DHA reduce arachidonic acid availability for COX/LOX pathways while STLs directly alkylate and inhibit NF-κB, targeting inflammation through parallel and non-redundant molecular mechanisms.

Safety & Interactions

At in vitro concentrations of 500–1000 µg/mL, Asteraceae polyphenol extracts exhibit cytotoxic effects—reducing cell viability to 47–82% of controls—though direct translation of these thresholds to human toxicological risk at typical supplemental doses is not established and requires in vivo pharmacokinetic data. Arnica montana is contraindicated for internal use in non-homeopathic doses due to sesquiterpene lactone toxicity causing gastroenteritis, cardiac arrhythmia, and mucosal damage; topical use is safe at standardized concentrations (0.5–1.0% STLs) but may cause contact dermatitis, particularly in individuals sensitive to the Asteraceae/Compositae family. Individuals with known Compositae allergy (affecting up to 5% of atopic populations) face cross-reactivity risk across multiple Asteraceae species and should avoid family-wide preparations; pregnancy and lactation represent contraindications for tansy (due to thujone) and arnica (systemic use). No specific drug-drug interaction data is available from the reviewed literature; general caution is warranted with anticoagulant medications (e.g., warfarin) given the flavonoid content's theoretical platelet-modulating potential, and with immunosuppressants given anti-inflammatory pathway modulation.